新天地：富马酸亚铁原料药上市申请获批

南方财经网12-09

　　南财智讯12月9日电，新天地公告，新天地药业股份有限公司收到国家药品监督管理局的富马酸亚铁原料药上市申请批准通知书。该原料药适用于预防和治疗缺铁性贫血，通过补充铁元素改善血红蛋白合成，缓解贫血相关症状。审批结论为符合药品注册有关要求，批准注册，质量标准、标签及生产工艺照所附执行。生产企业为新天地药业股份有限公司，通知书有效期至2030年12月7日。

（文章来源：南方财经网）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2590289315?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-09 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590289315","market":"hk","top_or_hot":-1,"title":"新天地：富马酸亚铁原料药上市申请获批","media":"南方财经网","content":"<html><body><div>\n<p>　　南财智讯12月9日电，<span><a href=\"https://laohu8.com/S/301277\">新天地</a></span><span></span>公告，<span href=\"http://quote.eastmoney.com/unify/r/0.301277\" target=\"_blank\" web=\"1\">新天地</span>药业股份有限公司收到国家药品监督管理局的富马酸亚铁原料药上市申请批准通知书。该原料药适用于预防和治疗缺铁性贫血，通过补充铁元素改善血红蛋白合成，缓解贫血相关症状。审批结论为符合药品注册有关要求，批准注册，质量标准、标签及生产工艺照所附执行。生产企业为<span href=\"http://quote.eastmoney.com/unify/r/0.301277\" target=\"_blank\" web=\"1\">新天地</span>药业股份有限公司，通知书有效期至2030年12月7日。 </p><p>（文章来源：南方财经网）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新天地：富马酸亚铁原料药上市申请获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新天地：富马酸亚铁原料药上市申请获批\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">南方财经网</strong><span class=\"h-time small\">2025-12-09 16:10</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　南财智讯12月9日电，<span><a href=\"https://laohu8.com/S/301277\">新天地</a></span><span></span>公告，<span href=\"http://quote.eastmoney.com/unify/r/0.301277\" target=\"_blank\" web=\"1\">新天地</span>药业股份有限公司收到国家药品监督管理局的富马酸亚铁原料药上市申请批准通知书。该原料药适用于预防和治疗缺铁性贫血，通过补充铁元素改善血红蛋白合成，缓解贫血相关症状。审批结论为符合药品注册有关要求，批准注册，质量标准、标签及生产工艺照所附执行。生产企业为<span href=\"http://quote.eastmoney.com/unify/r/0.301277\" target=\"_blank\" web=\"1\">新天地</span>药业股份有限公司，通知书有效期至2030年12月7日。 </p><p>（文章来源：南方财经网）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202512093586451855.html\">南方财经网</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://finance.eastmoney.com/a/202512093586451855.html","article_id":"2590289315","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590289315","pubTimestamp":1765267846,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"南财智讯12月9日电，新天地公告，新天地药业股份有限公司收到国家药品监督管理局的富马酸亚铁原料药上市申请批准通知书。该原料药适用于预防和治疗缺铁性贫血，通过补充铁元素改善血红蛋白合成，缓解贫血相关症状。审批结论为符合药品注册有关要求，批准注册，质量标准、标签及生产工艺照所附执行。生产企业为新天地药业股份有限公司，通知书有效期至2030年12月7日。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"301277":"新天地","BK0239":"医药制造"},"translate_title":"Xintiandi: The application for ferrous fumarate API marketing was approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301277":1.5},"content_text":"南财智讯12月9日电，新天地公告，新天地药业股份有限公司收到国家药品监督管理局的富马酸亚铁原料药上市申请批准通知书。该原料药适用于预防和治疗缺铁性贫血，通过补充铁元素改善血红蛋白合成，缓解贫血相关症状。审批结论为符合药品注册有关要求，批准注册，质量标准、标签及生产工艺照所附执行。生产企业为新天地药业股份有限公司，通知书有效期至2030年12月7日。 （文章来源：南方财经网）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590289315","isCrawlerRequest":true}